Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 753 clinical trials
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

stage iv breast cancer
primary tumor
erbb2
HER2
breast cancer
  • 0 views
  • 16 Feb, 2024
  • 16 locations
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC

primary tumor
lymphadenectomy
HER2
serum pregnancy test
12 lead electrocardiogram
  • 0 views
  • 05 Aug, 2020
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

anticoagulant therapy
stage iv breast cancer
central nervous system disease
immunohistochemistry
mk-3475
  • 8 views
  • 05 Aug, 2020
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

carcinoma
anthracycline
progressive disease
serum pregnancy test
advanced solid tumor
  • 0 views
  • 05 Aug, 2020
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

immunohistochemistry
blood transfusion
sentinel node
anticoagulants
g-csf
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients

The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and …

calcipotriene
psori-cm01
calcipotriol
psoriasis
psoriasis vulgaris
  • 0 views
  • 16 Feb, 2024
  • 1 location
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes

This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with Luminal A or Luminal B breast cancer, with the aim to collect valuable biological material from …

luminal
luminal a breast cancer
luminal b breast cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients (EEBC)  

The elderly patients over 65 years old with breast cancer have concomitant diseases, poor tolerance to conventional treatment, and the specific prognosis of breast cancer is relatively good. Previous studies on breast cancer have almost excluded elderly breast cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis and …

  • 0 views
  • 16 Jun, 2023
  • 1 location
reatment Standards and Outcomes of Patients With ER/PR Positive HER2-negative Metastatic Breast Cancer

To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

stage iv breast cancer
HER2
breast cancer
cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

Retrospective observational, multicentric study assessing the immunohistochemistry (IHC) based test IHC4 score in infiltrating early breast cancer: comparison of the score performed in local laboratory vs in a central laboratory and concordance with a molecular gold standard classifier (EndoPredict).

immunohistochemistry
ffpe
cancer
breast cancer
invasive breast cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location